STAT August 5, 2024
Adam Feuerstein

Struggling to find new patients, BioMarin Pharmaceuticals on Monday said it would restrict sales of its gene therapy for hemophilia A to three countries where it is currently approved, including the United States — a restructuring intended to reduce costs and help the treatment become profitable by next year.

The one-time treatment called Roctavian was approved in Europe in 2022 and in the U.S. in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
Key Trends in the Evolution of PBMs and Their Future Impact on Drug Pricing and Pharmacy Operations

Share This Article